PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein
Phosphatase of regenerating liver 3 (PRL3) is usually found intracellularly, and is over-expressed in cancer cells. Here the authors show that PRL-3 is also detectable on cell surface, and can be recognized by PRL3-zumab to recruit immune cells into tumor to promote anti-tumor immunity, thereby impl...
Main Authors: | Min Thura, Abdul Qader Al-Aidaroos, Abhishek Gupta, Cheng Ean Chee, Soo Chin Lee, Kam Man Hui, Jie Li, Yeoh Khay Guan, Wei Peng Yong, Jimmy So, Wee Joo Chng, Chin Hin Ng, Jianbiao Zhou, Ling Zhi Wang, John Shyi Peng Yuen, Henry Sun Sien Ho, Sim Mei Yi, Edmund Chiong, Su Pin Choo, Joanne Ngeow, Matthew Chau Hsien Ng, Clarinda Chua, Eugene Shen Ann Yeo, Iain Bee Huat Tan, Joel Xuan En Sng, Nicholas Yan Zhi Tan, Jean Paul Thiery, Boon Cher Goh, Qi Zeng |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2019-06-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-019-10127-x |
Similar Items
-
PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein
by: Thura, Min, et al.
Published: (2019) -
PRL3 induces polypoid giant cancer cells eliminated by PRL3-zumab to reduce tumor relapse
by: Min Thura, et al.
Published: (2021-07-01) -
Author Correction: PRL3 induces polyploid giant cancer cells eliminated by PRL3-zumab to reduce tumor relapse
by: Min Thura, et al.
Published: (2021-11-01) -
Exploiting frequent and specific expression of PRL3 in pediatric solid tumors for first-in-child use of PRL3-zumab humanized antibody
by: Amos Hong Pheng Loh, et al.
Published: (2023-09-01) -
Engineering the first chimeric antibody in targeting intracellular PRL-3 oncoprotein for cancer therapy in mice
by: Guo, Ke, et al.
Published: (2013)